Zhitong Financial App News, Deqi Pharmaceutical-B (06996.HK) issued an announcement. The Malaysian National Drug Administration has approved a supplementary new drug marketing application (SnDA) for Sivio® (Selinisol) to treat adult patients with recurrent or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two lines of systematic treatment and are not compatible with autologous stem cell transplantation.

Zhitongcaijing · 1d ago
Zhitong Financial App News, Deqi Pharmaceutical-B (06996.HK) issued an announcement. The Malaysian National Drug Administration has approved a supplementary new drug marketing application (SnDA) for Sivio® (Selinisol) to treat adult patients with recurrent or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two lines of systematic treatment and are not compatible with autologous stem cell transplantation.